MDNA413

MDNA413 is a novel, engineered IL-13 Superkine antagonist designed to selectively bind with high affinity to the Type II IL-4 receptor (IL-4Rα/IL-13Rα1) and potently block both IL-4 and IL-13 signaling. This recombinant fusion protein consists of an IL-4/IL-13 super-antagonist fused to an Fc domain for half-life extension. Its mechanism targets immunosuppressive cells in the tumor microenvironment (TME), such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), which are implicated in cancer growth and resistance to immunotherapy. By inhibiting pro-tumor immune pathways mediated by these cytokines, MDNA413 aims to reprogram "cold" tumors into inflamed, immune-responsive states. Preclinical studies have demonstrated its ability to inhibit tumor growth as monotherapy and synergistically when combined with an IL‑2 super‑agonist[1][3][5][6][9].

Other names

long-acting IL-13 super-antagonistlong-acting IL-4/IL-13 super-antagonistIL-13 superkineIL13 superkineIL 13 superkine